Farxiga (Dapagliflozin) Caregiver Administration Guide for Adolescents Ages 12 to 17

What Farxiga Does and Why It Is Prescribed to Teenagers

Farxiga belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It blocks the SGLT2 protein in the kidney's proximal tubule, which normally reabsorbs about 90% of filtered glucose back into the bloodstream. By blocking this transporter, dapagliflozin causes the kidneys to excrete roughly 60 to 80 grams of glucose per day in urine, lowering blood glucose independently of insulin [1].

Approved Indications for the 12 to 17 Age Group

The FDA approved dapagliflozin for pediatric patients in this age range in 2023, making it the first SGLT2 inhibitor approved as an adjunct to insulin in adolescents with type 1 diabetes [2]. In type 2 diabetes, it is approved as monotherapy or in combination with metformin or other agents when lifestyle changes and existing therapy are insufficient.

The FDA's approval in type 1 was supported by the DEPICT-1 and DEPICT-2 trials, both enrolling patients ages 10 and older. DEPICT-1 (N=143 in the pediatric sub-cohort) showed a statistically significant reduction in HbA1c of approximately 0.4 percentage points versus placebo at 24 weeks, along with reductions in total daily insulin dose and body weight [3].

How Dapagliflozin Differs From Insulin

Dapagliflozin's glucose-lowering action does not depend on beta-cell function or insulin sensitivity. This makes it useful across both type 1 and type 2 disease. The mechanism also produces mild caloric loss (roughly 240 to 320 kcal/day from glucosuria), a small blood-pressure benefit through osmotic diuresis, and renal protection in patients who already have albuminuria [4].

Correct Dosing for Adolescents: Type 1 vs. Type 2

The correct dose depends on the diagnosis. Getting this wrong exposes the teenager to either subtherapeutic blood glucose control or an elevated risk of DKA.

Type 1 Diabetes: 5 mg Once Daily, No Upward Titration

For type 1, the approved dose is exactly 5 mg once daily. The prescribing information explicitly states that the dose should not be increased to 10 mg in type 1 because the DKA signal is dose-dependent in this population [2]. When starting dapagliflozin in a type 1 patient, the prescriber will typically reduce the basal insulin dose by 20% on day one to prevent hypoglycemia. Caregivers should confirm this adjustment was communicated before giving the first tablet.

Type 2 Diabetes: 5 mg Starting Dose, Optional Escalation to 10 mg

In type 2 adolescents, the starting dose is 5 mg once daily. If HbA1c remains above target after 8 to 12 weeks and the patient tolerates the 5 mg dose without significant urinary symptoms or volume depletion, the prescriber may increase the dose to 10 mg once daily [2]. Caregivers should not adjust the dose on their own; any escalation requires a prescriber order and a repeat kidney function check.

Weight-Based Considerations

Unlike many pediatric medications, dapagliflozin dosing for this age group is not weight-based. The fixed 5 mg dose was validated across a range of body weights in the DEPICT trials. The mean body weight of adolescent participants in DEPICT-2 was approximately 67 kg, with a range that included patients under 50 kg and over 100 kg; efficacy and safety profiles were broadly consistent across this range [3].

Step-by-Step Administration Instructions for Caregivers

Consistency in timing and technique reduces dosing errors. Follow these steps every day.

Preparing the Dose

1. Check that the tablet in hand matches what was dispensed: Farxiga 5 mg tablets are pale yellow and film-coated; 10 mg tablets are yellow-orange. Both are diamond-shaped.
2. Verify the prescription label says "dapagliflozin" (generic) or "Farxiga" (brand). Confirm the strength printed on the label matches what the prescriber ordered.
3. Wash hands before handling the tablet.

Giving the Tablet

• Give dapagliflozin once daily, preferably in the morning. Morning dosing means the peak glucosuric effect occurs during waking hours, reducing the likelihood of overnight voiding that disrupts sleep.
• The tablet may be taken with or without food. No crushing or splitting is needed or recommended; the tablet is already a low volume and swallowed whole.
• Pair administration with at least 8 ounces (240 mL) of water to support the increased urinary flow the drug produces.
• If a dose is missed and it is still the same morning, give it as soon as remembered. If it is already afternoon or the next day, skip the missed dose and resume the regular schedule. Never double-dose.

Confirming Swallowing

In teenagers who have difficulty swallowing tablets, confirm the tablet has been fully swallowed and not held under the tongue or discarded. The film coating dissolves quickly; if the teen reports a slightly bitter taste, that is normal and not a sign of an allergic reaction.

Safety Monitoring: What Caregivers Must Watch For

The safety signals for dapagliflozin in adolescents mirror those seen in adults but may present differently or progress faster in younger patients who are more physically active or who participate in sports.

Diabetic Ketoacidosis: The Most Serious Risk

DKA is the most serious adverse effect of SGLT2 inhibitors in type 1 diabetes. Critically, dapagliflozin can cause euglycemic DKA, meaning ketones accumulate to dangerous levels even when the blood glucose reading is in a range that looks acceptable (often 150 to 250 mg/dL rather than the classic 300+ mg/dL) [5].

The FDA issued a safety communication in 2015 and updated DKA warnings for all SGLT2 inhibitors in subsequent label revisions [6]. The prescribing information for Farxiga carries a bolded warning about this risk in type 1.

Caregivers should measure blood or urine ketones, not just glucose, in any of these situations:

• Nausea, vomiting, or abdominal pain
• Unusual fatigue or drowsiness
• Decreased food intake for more than 12 hours
• Rapid breathing or fruity-smelling breath
• Any febrile illness lasting more than 24 hours

A practical decision rule for caregivers: if blood ketones exceed 0.6 mmol/L or urine ketones are moderate or large, withhold dapagliflozin, give a correction insulin dose per the existing sick-day protocol, call the prescriber or diabetes care team, and go to the emergency department if ketones do not clear within 2 to 4 hours or the teenager's condition worsens.

Urinary Tract and Genital Infections

SGLT2 inhibitors increase urinary glucose concentration, which feeds bacterial and fungal growth. In the pooled DEPICT adult-equivalent analysis, genital mycotic infections occurred in approximately 9 to 12% of female patients on dapagliflozin versus 2 to 3% on placebo [3]. Rates in male patients were lower but still elevated.

Caregivers should teach adolescents, particularly female patients, to:

• Wipe front-to-back after using the toilet.
• Change out of wet swimwear or athletic clothing promptly.
• Report itching, discharge, or burning to a parent or provider without embarrassment.

Urinary tract infections (UTIs) require prompt evaluation. A UTI that ascends to the kidney (pyelonephritis) in a patient on an SGLT2 inhibitor should prompt temporary discontinuation pending resolution [2].

Volume Depletion and Orthostatic Hypotension

The osmotic diuresis from glucosuria can deplete intravascular volume, which matters most during hot weather, intense athletic activity, or gastrointestinal illness. Signs include dizziness when standing, decreased urine output despite ongoing thirst, dry mouth, and fatigue that worsens over days.

Adolescents who play competitive sports should drink an additional 16 to 24 ounces of water per hour of vigorous activity beyond their normal hydration habit. Hold dapagliflozin on days of prolonged exercise in extreme heat until the prescriber has reviewed the plan.

Bone Health Considerations

Adult data from DECLARE-TIMI 58 (N=17,160) showed no significant increase in fracture risk with dapagliflozin at 4.2 years of follow-up [7]. Adolescence is a period of active bone mineral accrual, so any caregiver who notices a fracture after minor trauma, or a teenager who reports bone pain, should mention dapagliflozin use to the treating clinician.

Sick-Day Rules: When to Hold the Tablet

The three-day hold rule is one of the most important operational instructions for caregivers of teenagers on dapagliflozin.

The Three-Day Preoperative Stop

Before any surgical or dental procedure requiring general anesthesia, sedation, or prolonged fasting, dapagliflozin must be stopped at least 3 calendar days (72 hours) in advance [2]. This window allows the kidney to resume normal glucose reabsorption and reduces DKA risk during perioperative fasting and physiologic stress. The surgeon or anesthesiologist may extend this hold. Caregivers should proactively inform every procedural team that their teenager takes this medication.

Acute Illness Protocol

Stop dapagliflozin on the first day of any of these conditions:

• Vomiting or diarrhea causing reduced oral intake for more than 12 hours
• Fever above 101°F (38.3°C) persisting beyond 24 hours
• Inability to drink at least 4 to 6 cups of fluid per day

Resume dapagliflozin only after the teenager has been eating and drinking normally for at least 24 hours and blood or urine ketones are negative or trace.

Extreme Heat and Exercise

Adolescents who train or compete in hot conditions face compounded dehydration risk. Sports medicine data suggest that high-school athletes can lose 1 to 2 liters of sweat per hour during outdoor summer practice [8]. On such days, the safest course is to hold dapagliflozin and contact the prescriber the same day to discuss reinstatement after the event.

Drug Interactions Caregivers Should Know

Dapagliflozin itself has a limited drug-drug interaction profile because it is metabolized primarily by UGT1A9 glucuronidation rather than by CYP450 enzymes [2]. Still, several combinations deserve attention in adolescents.

Insulin and Sulfonylureas: Hypoglycemia Risk

Adding dapagliflozin to insulin (type 1) or to a sulfonylurea such as glipizide (type 2) raises hypoglycemia risk. The DEPICT trials required a planned 20% basal insulin reduction at dapagliflozin initiation in type 1 patients. Caregivers should keep rapid-acting glucose (glucose tablets, juice, or glucagon) available and know the teen's individual hypoglycemia action plan [3].

Diuretics: Volume Depletion Compounded

Teenagers on thiazide or loop diuretics for hypertension, heart failure, or edema face additive volume depletion when dapagliflozin is added. The prescriber should reassess diuretic dosing before starting dapagliflozin and at the 2 to 4 week follow-up visit.

NSAIDs and Contrast Dye

Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) reduce renal blood flow and may impair the kidney's ability to compensate for the osmotic effects of dapagliflozin. Avoid routine NSAID use while on this medication. Before any imaging study using iodinated contrast dye, caregivers should notify the radiology team, as contrast nephropathy protocols may require a temporary hold of dapagliflozin based on baseline eGFR [2].

Kidney Function Monitoring Requirements

Dapagliflozin's glucose-lowering mechanism depends on adequate kidney filtration. Regular kidney function testing is not optional.

Pre-Treatment Baseline

Before the first dose, the prescribing team should have ordered a basic metabolic panel or comprehensive metabolic panel that includes serum creatinine and an estimated GFR (eGFR). If eGFR is below 45 mL/min/1.73 m², dapagliflozin should not be started in type 1 or type 2 adolescents [2].

Ongoing Monitoring Schedule

The American Diabetes Association's Standards of Care recommend monitoring kidney function annually in pediatric patients with diabetes who are on medications that affect renal hemodynamics [9]. In practice, most prescribers check eGFR and urine albumin-to-creatinine ratio (UACR) at:

• Baseline (before starting)
• 3 months after initiation
• Every 6 to 12 months thereafter, depending on baseline kidney health

Caregivers should bring their teenager to all scheduled lab appointments, even if the teen feels well. Early detection of declining eGFR allows dose adjustment or discontinuation before significant kidney injury occurs.

Special Situations: Sports, Travel, and Transition to Adult Care

Athletics and Competitive Sports

Active adolescents on dapagliflozin can continue organized sports with appropriate planning. The key steps are:

• Carry glucose tablets and a ketone meter in the sports bag.
• Inform coaches that the athlete has diabetes and is on an SGLT2 inhibitor.
• Pre-hydrate with at least 16 ounces of water or electrolyte solution 30 to 60 minutes before practice.
• Check blood or urine ketones after any practice lasting more than 90 minutes if the athlete used significant insulin reduction.

The American Diabetes Association's 2024 position statement on physical activity notes that carbohydrate consumption during exercise remains the primary hypoglycemia prevention strategy in insulin-requiring patients, and SGLT2 inhibitor use does not eliminate this need [9].

Traveling Across Time Zones

Once-daily dapagliflozin has a terminal half-life of approximately 12.9 hours, giving caregivers flexibility when crossing time zones [2]. When traveling east and losing hours, give the dose at the destination morning. When traveling west and gaining hours, skip the extra dose opportunity and take one tablet the morning after arrival. Never give two doses within an 18-hour window.

Transition Planning from Pediatric to Adult Care

Most pediatric endocrinology practices begin transition planning by age 15 to 16. During this period, caregivers should gradually shift tablet administration responsibility to the teenager, with oversight. The American Academy of Pediatrics recommends that by age 17, the teenager should be able to describe their medications, doses, and indications independently [10]. Caregivers can use pill-tracking apps or a weekly pill organizer to support this transition without abruptly withdrawing supervision.

When to Call the Prescriber or Go to the Emergency Department

Caregivers sometimes delay seeking care because glucose readings look "okay." With SGLT2 inhibitors, normal glucose does not rule out DKA.

Call the prescriber or diabetes care team the same day if:

• Blood ketones are 0.6 to 1.5 mmol/L and the teenager is drinking fluids and feels reasonably well.
• The teenager has a UTI with dysuria, frequency, or low-grade fever.
• There are signs of a genital yeast infection that have not responded to one course of over-the-counter antifungal treatment.
• The teen is scheduled for any surgery and the surgical team has not been told about dapagliflozin.

Go to the emergency department immediately if:

• Blood ketones exceed 1.5 mmol/L, or urine ketones are large, regardless of glucose level.
• The teenager is vomiting and cannot retain oral fluids.
• There is rapid or labored breathing, confusion, or extreme weakness.
• Blood glucose exceeds 300 mg/dL and ketones are present.

The ISPAD (International Society for Pediatric and Adolescent Diabetes) Clinical Practice Consensus Guidelines state: "SGLT2 inhibitor-associated DKA requires prompt recognition and should be treated with the same urgency as classic DKA, with early fluid resuscitation and insulin infusion titrated to ketone clearance rather than to glucose normalization alone" [11].

Storage, Disposal, and Practical Household Tips

Correct Storage

Farxiga tablets should be kept at room temperature, 68 to 77°F (20 to 25°C), in the original prescription bottle with the cap tightly closed. Do not store in the bathroom medicine cabinet (humidity) or on the kitchen windowsill (temperature fluctuation). If the household temperature regularly exceeds 86°F (30°C) in summer, store the bottle in an insulated medication case.

Safe Disposal

Do not flush unused dapagliflozin tablets. The FDA's preferred disposal method for most medications outside of a drug-take-back program is to mix tablets with an unappealing substance (coffee grounds, dirt, or cat litter), seal in a bag, and discard in household trash [12]. Check DEA drug-take-back locator for a nearby pharmacy disposal kiosk.

Pill Tracking for Adolescents

A weekly pill organizer loaded by the caregiver on Sunday morning reduces missed-dose confusion. If the teenager takes the tablet independently, a smartphone alarm labeled "Farxiga morning" reinforces the habit without the caregiver needing to remind them daily, which supports adolescent autonomy.